Get the Stockscreener App
4.01
0.50%
0.02
Pre-market:
4.11
0.10
+2.49%
Exagen Inc stock is traded at $4.01, with a volume of 198.87K.
It is up +0.50% in the last 24 hours and down -22.14% over the past month.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
See More
Previous Close:
$3.99
Open:
$4.05
24h Volume:
198.87K
Relative Volume:
1.53
Market Cap:
$70.73M
Revenue:
$52.55M
Net Income/Loss:
$-23.69M
P/E Ratio:
-4.266
EPS:
-0.94
Net Cash Flow:
$-15.29M
1W Performance:
+33.67%
1M Performance:
-22.14%
6M Performance:
+104.59%
1Y Performance:
+102.53%
1-Day Range:
$3.72
$4.20
1-Week Range:
$2.76
$4.20
52-Week Range:
$1.3003
$6.22
Exagen Inc Stock (XGN) Company Profile
Name
Exagen Inc
Sector
Industry
Phone
(760) 560-1501
Address
1261 LIBERTY WAY, VISTA, CA
Compare XGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
4.01 | 70.73M | 52.55M | -23.69M | -15.29M | -0.94 |
|
TMO
Thermo Fisher Scientific Inc
|
573.06 | 219.20B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
244.11 | 176.31B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
152.57 | 43.57B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
205.69 | 37.33B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
427.33 | 34.99B | 3.84B | 866.24M | 792.60M | 10.37 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Apr-15-21 | Initiated | Canaccord Genuity | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-14-19 | Initiated | Cowen | Outperform |
| Oct-14-19 | Initiated | William Blair | Outperform |
View All
Exagen Inc Stock (XGN) Latest News
Exagen Gains 28%, Insider Trades Reap Benefit - Yahoo Finance
The 26% return this week takes Exagen's (NASDAQ:XGN) shareholders one-year gains to 102% - Simply Wall St
Exagen Inc. (XGN) Soars to 52-Week High, Time to Cash Out? - MSN
Exagen Inc. Gains Approval for Advanced Lupus and Rheumatoid Arthritis Diagnostic Tests - Lupus Foundation of America
Exagen’s (XGN) “Overweight” Rating Reaffirmed at Cantor Fitzgerald - Defense World
Cantor Fitzgerald Reaffirms "Overweight" Rating for Exagen (NASDAQ:XGN) - MarketBeat
Exagen Inc. Secures Conditional NY State Approval for New - GlobeNewswire
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis - The Bakersfield Californian
Exagen Achieves Record $55.8M Revenue, Gets NY Approval for New Lupus & RA Biomarker Tests - StockTitan
Exagen (NASDAQ:XGN) Given New $7.00 Price Target at Canaccord Genuity Group - Defense World
Exagen (NASDAQ:XGN) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says - MarketBeat
Short Interest in Exagen Inc. (NASDAQ:XGN) Grows By 36.5% - Defense World
Exagen Inc. (NASDAQ:XGN) Short Interest Up 36.5% in December - MarketBeat
Exagen (NASDAQ:XGN) Stock Price Up 1.4%Time to Buy? - MarketBeat
Exagen (NASDAQ:XGN) Trading 1.4% Higher – Still a Buy? - Defense World
Exagen Inc.'s (NASDAQ:XGN) Share Price Boosted 26% But Its Business Prospects Need A Lift Too - Simply Wall St
Learn to Evaluate (XGN) using the Charts - Stock Traders Daily
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD - GlobeNewswire
Exagen Hits Major Milestone: 1 Million AVISE Tests Revolutionize Autoimmune Disease Diagnosis - StockTitan
Exagen stock soars to 52-week high, hits $4.97 - Investing.com
Exagen's SWOT analysis: diagnostic firm's stock poised for growth amid challenges By Investing.com - Investing.com South Africa
Exagen's SWOT analysis: diagnostic firm's stock poised for growth amid challenges - Investing.com India
Exagen stock soars to 52-week high, hits $4.88 amid robust gains By Investing.com - Investing.com South Africa
Exagen stock soars to 52-week high, hits $4.88 amid robust gains - Investing.com Canada
Wasatch Advisors LP Sells 272,054 Shares of Exagen Inc. (NASDAQ:XGN) - MarketBeat
Exagen stock holds Sector Weight amid mixed 3Q24 results By Investing.com - Investing.com Nigeria
Exagen stock soars to 52-week high, hits $3.79 By Investing.com - Investing.com Canada
Exagen CEO, President & Director Acquires 7.7% More Stock - Simply Wall St
Exagen stock soars to 52-week high, hits $3.79 - Investing.com India
Exagen CFO Jeffrey Black acquires $66,448 in common stock - Investing.com India
Exagen CFO Jeffrey Black acquires $66,448 in common stock By Investing.com - Investing.com UK
Exagen president and CEO John Aballi buys $68,297 in stock By Investing.com - Investing.com Canada
Exagen president and CEO John Aballi buys $68,297 in stock - Investing.com
What is William Blair’s Forecast for Exagen FY2024 Earnings? - Defense World
Research Analysts Issue Forecasts for Exagen FY2024 Earnings - MarketBeat
FY2024 EPS Estimates for Exagen Raised by Cantor Fitzgerald - MarketBeat
Cantor Fitzgerald Increases Earnings Estimates for Exagen - Defense World
Exagen Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
William Blair Reiterates “Outperform” Rating for Exagen (NASDAQ:XGN) - Defense World
Exagen unveils new biomarkers to enhance autoimmune testing - Investing.com
Exagen Inc. Completes Validation and Regulatory Submission - GlobeNewswire
Exagen Enhances AVISE CTD Platform with 7 New Biomarkers for Autoimmune Disease Detection | XGN Stock News - StockTitan
Exagen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Exagen Inc. to Participate in Fourth Quarter Investor Conferences - The Manila Times
Exagen CEO to Present at Three Major Healthcare Investor Conferences | XGN Stock News - StockTitan
Exagen (NASDAQ:XGN) Receives Outperform Rating from William Blair - MarketBeat
Exagen Inc. (NASDAQ:XGN) Q3 2024 Earnings Call Transcript - Insider Monkey
Exagen Inc Stock (XGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):